Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation

• Main Authors: Xiaoyu Zhang (Author), Xiaoli Zhao (Author), Yuyan Shen (Author), Yuanyuan Shi (Author), Lining Zhang (Author), Mengze Hao (Author), Fei Zhao (Author), Rongli Zhang (Author), Jialin Wei (Author), Sizhou Feng (Author), Yi He (Author), Erlie Jiang (Author), Mingzhe Han (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary complication of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we retrospectively identified seven patients newly diagnosed with BOS post HSCT and analyz...